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Results: Nine false-positives (9.8%) were found in the retrospective cohort (N¼ 92).
These were initially diagnosed as MSI and/or dMMR by the originating institute but
were reclassified as MMR proficient /microsatellite stable in our laboratory
(PPV¼90.2%; 95%CI, 82.2-95.0). The PPV in the prospective cohort (N¼ 39) was
92.3% (95%CI, 79.0-98.1), with the 3 false-positive patients experiencing progressive
disease with ICKi treatment. Amongst the 119 true-positive mCRCs, the detection rate
and sensitivity were respectively 100% and 95.8% for immunohistochemistry, while for
pentaplex PCR these were 81.5% and 95.9%. Only the combination of immunohisto-
chemistry and pentaplex PCR methods resulted in 100% detection rate and 100%
sensitivity.
Conclusions: Local assessment of MSI/dMMR status in mCRC resulted in misdiagno-
sis of 9.1% of cases as false positive and subsequently incorrect treatment with ICKi.
We recommend new guidelines that mandate dual testing of mCRC samples in experi-
enced diagnostic centers using both PCR and immunohistochemistry.
Legal entity responsible for the study: INSERM.
Funding: ARCAD Foundation, Institut National du Cancer, Ligue Contre Le Cancer.
Disclosure: T. André: Consultancy: Bristol-Myers Squibb, Fees: Merck. All other
authors have declared no conflicts of interest.
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Background: Tumors expressing programmed death ligand 1 (PD-L1) can render
immune inactivated via triggering of PD-1 receptor on T cells with various pathways.
Based on this mechanism, the blockade PD-1/PD-L1 pathway has been used as a thera-
peutic target for metastatic CRC. In the present study, we evaluated the prognostic role
of PD-L1 expression associated with microsatellite status in surgically resected stage III
colon cancer patients.
Methods: PD-L1 expression was performed by immunohistochemistry from 182 stage
III colon cancer patients after curative resection. The percentage of PD-L1 positive
tumor cells and staining intensity were evaluated and categorized as ‘strong’ or ‘weak’
positive group. Clinical and histopathologic parameters including of MSI status and
survival outcomes were analyzed with IDO expression which stands for the suppressive
immune environment.
Results: Strong PD-L1 expression was observed in 29% of all patients. Perineural inva-
sion and lymphocyte response were more frequently shown in strong expression of PD-
L1 grop. Among resected patients, MSI was shown in 23 patients (12%). Although there
was no significant difference between microsatellite status and PD-L1 expression,
strong PD-L1 tended to better overall survival in microsatellite stable (MSS) colon can-
cer (P¼ 0.056). In contrast, strong PD-L1 expression was significantly correlated with
worse DFS (P¼ 0.001) and OS (P< 0.001) than weak PD-L1 expression group in
microsatellite instability (MSI) patients, regardless of adjuvant chemotherapy. Also, the
strong IDO expression was tended to be more frequently shown in strong PD-L1
expression (36.4%) group than weak PD-L1 expression (14.3%) group in MSI patients.
Conclusions: The expression of PD-L1 is differently affected on the survival outcomes
according to the status of microsatellite. There is no significant relationship between
the expression of PD-L1 and prognosis in MSS stage III colon cancer patients.
However, in MSI colon cancer which has been well known as a highly immunogenic
property, strong PD-L1 expression is significantly associated with poor prognosis on
survival outcomes reflecting the immunosuppressive microenvironment in curative
resected stage III colon cancer patient.
Funding: Has not received any funding.
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Background: Obesity is a well-established risk factor for colorectal cancer (CRC), but
whether this risk differs according to CRC subtype defined by the tumor immune
microenvironment has been sparsely described. Herein, we examined the relationship
between pre-diagnostic anthropometry and CRC risk according to tumor-infiltrating
immune cell composition, with particular reference to potential sex differences.
Methods: The density of immune cells expressing PD1, PD-L1 (PD-L1/IC), CD3, CD8,
FoxP3, CD20, CD68, CD163, and tumor cells expressing PD-L1 (PD-L1/TC) was
assessed by immunohistochemistry in tissue microarrays with tumors from 584
incident CRC cases in the Malmö Diet and Cancer Study (n¼ 28098). Multivariable
Cox regression models, adjusted for age, smoking and alcohol intake, were applied to
calculate hazard ratios (HR) for CRC risk according to height, weight, bodyfat %,
waist- and hip circumference, waist-hip ratio (WHR), body mass index (BMI), and dif-
ferent immune cell subsets.
Results: Obesity, measured as several anthropometric factors, was significantly associ-
ated with PD-L1þ/TC low, CD8þ high, FoxP3þ low, CD20þ low, and CD163þ low
tumors in both sexes, and with PD1þ low tumors in women. A contrasting risk between
sexes was seen for PD-L1/ICþ tumors, in that obesity was significantly associated with
risk of PD-L1/ICþ high tumors in women (ptrend for weight¼ 0.008, ptrend for BMI¼
0.039), but with risk of PD-L1/ICþ low tumors in men (ptrend for weight¼ 0.005, ptrend
for bodyfat %¼ 0.003, ptrend for waist<0.001, ptrend for hip¼ 0.012, ptrend for BMI¼
0.001, ptrend for WHR<0.001). Furthermore, obesity was associated with risk of any
CD3þ high or low and any CD68þ high or low tumors in both sexes, and with any
PD1þ high or low tumors in men. In age and BMI-adjusted survival analysis, PD1þ,
CD8þ, CD20þ, and CD68þ high were favorable prognostic factors only in women, and
FoxP3þ high only in men. High PD-L1þ and CD3þ expression was prognostic in both
sexes.
Conclusions: Anthropometric factors may influence the immune landscape of colorec-
tal cancer, possibly in a sex-dependent manner. Thus, obesity and sex may be important
factors to take into account when stratifying patients for immunotherapy.
Legal entity responsible for the study: Lund University.
Funding: Swedish Cancer Society, Swedish Research Council, the Swedish
Government Grant for Clinical Research, the Mrs Berta Kamprad Foundation, Lund
University Faculty of Medicine, University Hospital Research Grants.
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Background: Changes in peripheral blood cells composition may reflect tumor
immune microenvironment and its role in cancer growth control. High monocyte-to-
lymphocyte ratio (MLR) could be a sign of tumor’s recruitment of suppressive cells,
showing a prognostic role in many cancer types. This study aimed to evaluate the prog-
nostic role of MLR in metastatic colorectal cancer (MCRC).
Methods: This retrospective study analyzed a consecutive cohort of 392 patients (pts)
with MCRC treated in 2004-2017 at the Oncology Departments of Aviano and Udine
(Italy). The prognostic impact of MLR on overall survival (OS) was evaluated with uni
and multivariate Cox regression analyses. The best cut-off value to predict survival was
defined through ROC analysis.
Results: Before first line therapy, 269 pts (69%) were aged<70, 120 pts (31%) had a
right tumor, 150 pts (38%) a left tumor and 117 pts (30%) a rectal one. Of note, 105 pts
(27%) received metastasectomy and 142 pts had>1 metastasis. Metastasis were more
frequent in liver (40%), lung (20%) and peritoneum (20%) Overall, 57% had a KRAS
mutation (m) and 11% had a BRAFm. At median follow-up of 60 months, median OS
was 26 months. At univariate analysis, older age (HR 1.61, p< 0.001), nodes (pN2 HR
1.48, p¼ 0.036; pN3 HR 2.52, p¼ 0.001), KRASm (HR 1.36, p¼ 0.020) and MLR (HR
3.32, p< 0.001) were associated with worse OS. Conversely, sidedness (left HR 0.65,
p¼ 0.003; rectum HR 0.73, p¼ 0.042), metastasectomy (HR 0.36, p< 0.001) and adju-
vant chemotherapy (HR 0.66, p¼ 0.008) were associated with better OS. By multivari-
ate analysis, sidedness and metastasectomy confirmed a better OS, while MLR (HR
3.20, p< 0.001), nodes (pN2 HR 1.89, p¼ 0.006; pN3 HR 2.25, p¼ 0.014), and
KRASm (HR 1.50, p< 0.001) were associated with worse OS. The adoption of the cut-
off value for MLR (i.e. 0.44) predicted worse OS both in univariate (HR 2.23,
p< 0.001) and multivariate (HR 2.41; p< 0.001) analyses. Moreover, MLR was associ-
ated with number of metastatic sites (p< 0.001), type of sites (p< 0.001), sidedness
(p¼ 0.001) and LDH level (p< 0.001).
Conclusions: High MLR is an independent prognostic factor associated with worse OS
and pathological features of MCRC. Further studies are needed to confirm these data.
Legal entity responsible for the study: University of Udine.
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